Despite encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable resistance from managed care entities. The insurers are often https://phoenixdcsg421161.ezblogz.com/73884632/the-vyndamax-faces-is-encountering-pharmacy-benefit-manager-challenges-the-look-at-access-battles